- In April 2023, Novartis AG, a global leader in pharmaceuticals, announced the launch of a new fixed-dose combination eye drop designed for the comprehensive treatment of allergic conjunctivitis with associated inflammation. This development aims to provide a more convenient and effective option for patients, strengthening Novartis's position in the ophthalmic market
- In March 2023, Allergan (AbbVie Inc.) received FDA approval for a novel ophthalmic solution indicated for the treatment of infectious conjunctivitis caused by resistant bacterial strains. This approval highlights AbbVie's commitment to addressing unmet needs in eye care and combating antimicrobial resistance
- In March 2023, Bausch Health Companies Inc. initiated a Phase 3 clinical trial for an investigational antiviral eye drop designed for the treatment of adenoviral conjunctivitis, a highly contagious form of pink eye. This advancement could lead to the first specific antiviral treatment for this common condition, addressing a significant unmet medical need
- In February 2023, Santen Pharmaceutical Co., Ltd., a specialized ophthalmic company, entered into a strategic collaboration with a biotech firm to develop a new mast cell stabilizer eye drop with a unique mechanism of action for severe allergic conjunctivitis. This partnership aims to expand Santen's portfolio and offer improved therapeutic options for patients with chronic ocular allergies
- In January 2023, Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on eye diseases, announced positive results from its Phase 2 trial of a novel corticosteroid formulation for persistent allergic conjunctivitis, demonstrating improved efficacy and reduced dosing frequency. This development showcases Kala's innovation in drug delivery and its potential to capture a larger share in the allergic conjunctivitis segment
